Best Life Sciences Companies in Tampa, United States
The 77 best Life Sciences companies in Tampa, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Romark.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Tampa
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Romark Developer of therapeutics for infectious diseases | $116M | 111 mo ago | Series E | Marc Ayers CEO | 128 | — | — | — |
| 2 | Oragenics Developer of novel treatments for infectious diseases and oral mucositis as well as probiotics for oral health | $87M | 34 mo ago | Public | Alan Joslyn CEO & President | 5 | BootstrapApache HTTP ServerjQuery+8 | 123 patents Intranasal drug delivery systems for treating traumatic brain injury and concussion | 2 launchs |
| 3 | Sirion Therapeutics Developer of ophthalmic products for eye care | $72M | 202 mo ago | Acquired | Barry Butler Co-Founder & CEO | — | — | — | — |
| 4 | Concept Medical Developer of devices for treating cardiac disorders and diabetes | $60M | 94 mo ago | Series C | Kumaresan Pandurangan CISO & Director Of Information Technology | — | WordPressPleskMySQL+29 | — | — |
| 5 | TuHURA Biosciences Developer of immunotherapies for the treatment of cancer 42Funding top 20%Talent top 38%Moat top 39%Growth top 45% All 8 signals ▾Fundingtop 20% Talenttop 38% Moattop 39% Growthtop 45% Techbottom 47% Newsbottom 39% Globalbottom 36% Marketbottom 32% Funding: Raised $37.8M across 11 rounds · 11 rounds over 8 yrs (1.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $38M | 7 mo ago | Public | Patricia Lawman Co-Founder | — | WordPressMySQLPHP+16 | — | — |
| 6 | PainTEQ Innovative SI joint solutions for lasting pain relief and improved stability | $35M | 35 mo ago | Funding Raised | Chris Girsch Co-Founder | 22 | WordPressMySQLPHP+21 | — | 1 job opening |
| 7 | Mirror Biologics Developer of next-generation immunotherapy products | $30M | 44 mo ago | Series A | Michael Har-Noy Founder & CEO | 20 | — | 34 patents Engineered artificial lymph node bioreactors for cancer immunotherapy and vaccine development | — |
| 8 | InflammX Therapeutics Developer of therapeutics for ophthalmic disorders | $29M | 65 mo ago | Series B | Colin Green Co-Founder | 2 | — | — | — |
| 9 | Medingo Provider of minimally invasive device for insulin delivery | $27M | 223 mo ago | Series B | — | — | — | 4 patents Patents concentrated in health & consumer products | — |
| 10 | Teewinot Life Sciences Online game platform offering latest games with easy wins | $20M | 109 mo ago | Series B | — | 2 | — | — | — |
| 11 | Intezyne Clinical-stage company developing drugs for the treatment of various tumor diseases | $19M | 104 mo ago | Series A | — | 4 | — | 190 patents Nanocarrier drug delivery systems and ruthenium‑based anticancer compounds | — |
| 12 | Keystone Heart Embolic cerebral protection devices | $14M | 145 mo ago | Acquired | — | 33 | — | — | — |
| 13 | Procera Health Provider of nutritional products for brain health | $13M | 133 mo ago | Series B | Scott Eibel CEO | 19 | Cart FunctionalityShopifySentry+28 | — | — |
| 14 | Katena Ophthalmic surgical products for sight restoration, clinician support, and patient care | $8M | 150 mo ago | Acquired | — | 145 | — | — | — |
| 15 | Betaliq Developer of patented technology-based products for vision care | $6M | 13 mo ago | Series A | Barry Butler CEO | — | — | — | — |
| 16 | Modulation Therapeutics Developing innovative therapies targeting cancer and liver disease | $5M | 15 mo ago | Series A | Mark McLaughlin Co-Founder & EVP | — | — | — | — |
| 17 | Bioleap Provider of computational fragment-based technology for drug discovery | $5M | 153 mo ago | Series A | Wayne Mitchell CEO | 7 | — | 15 patents Industrial heat recovery and process energy integration for cooking, drying, and distillation | — |
| 18 | VuEssence Genome based diagnostic technology platform | $3M | 13 mo ago | Seed | Maha Sallam Founder & President | 5 | — | 2 patents Neurovascular disease diagnostics and gene‑expression‑targeted therapeutics | — |
| 19 | Psoria-Shield UV phototherapy treatment for psoriasis, eczema, and vitiligo. | $3M | 169 mo ago | Acqui-Hired | Scot Johnson CEO & President | — | — | — | — |
| 20 | Psilera Manufacturer of natural-based medicines for the treatment of mental health illnesses | $2M | 59 mo ago | Seed | Jackie Salm Co-Founder | 9 | — | 29 patents Pharmaceutical formulations of tryptamine derivatives and 5‑HT2A receptor ligands | — |
| 21 | Pilgrim Quality Solutions AI-enabled compliance solutions for life sciences, ensuring quality and regulatory adherence | $2M | 184 mo ago | Acquired | — | 98 | — | — | — |
| 22 | Asha Therapeutics Developer of therapeutics for neurodegenerative diseases | $1M | 46 mo ago | Seed | Bradlee Heckmann Co-Founder & CSO | — | WixSentryBootstrap+13 | — | — |
| 23 | SynDaver Synthetic humans and animals for medical simulation, training, and device testing | $1M | 130 mo ago | Late Stage | Christopher Sakezles Founder & CEO | 176 | Cart FunctionalityWooCommerceWordPress+32 | 13 patents Medical simulation models for canine anatomy and procedural training devices | — |
| 24 | KeriCure Developer of topical wound care products | $800K | 88 mo ago | Seed | Pam Sovine Managing Director | 5 | WordPress Block EditorCart FunctionalityEcwid+35 | — | — |
| 25 | Soilcea Developing HLB-resistant citrus trees using CRISPR technology for Florida's citrus industry | $750K | 15 mo ago | Seed | Chana Cannon Co-Founder & VP | 3 | WordPress Block EditorWordPressMySQL+9 | — | — |
| 26 | TransGenex Developer of 3D cell culture solutions and services for biopharma | $681K | 132 mo ago | Funding Raised | Shyam Mohapatra Co-Founder & Chairman | 6 | — | — | — |
| 27 | Cvergenx Genomic informatics company personalizing radiation therapy with precision genomic radiation therapy platform | $616K | 126 mo ago | Seed | — | 3 | — | 10 patents Genomics-driven personalized radiation therapy planning and dosing for head‑and‑neck cancers | — |
| 28 | Accentia Biopharmaceuticals Drugs and medical devices for autoimmune diseases | $375K | 168 mo ago | Public | Francis Odonnell CEO | — | — | 34 patents Optimizing high-dose oxazaphosphorine chemotherapy with patient selection, combo biologics, and mucositis care | — |
| 29 | Venn Therapeutics Developer of immunotherapies for treating cancer | $225K | 81 mo ago | Funding Raised | Sam Shrivastava Founder & CEO | 6 | — | — | — |
| 30 | ALPS South Prosthetic liners, sleeves, feet, and skincare solutions for improved mobility | $150K | 153 mo ago | Funding Raised | Aldo Laghi CEO | — | WordPress Block EditorWordPressMySQL+24 | 140 patents Advanced prosthetic liner textiles and ankle joint components for enhanced fit and function | 1 launch |
Top 12 Life Sciences companies in Tampa
#1
Public · Tampa, Florida · founded 1996$37.8Mraised▾
Developer of immunotherapies for the treatment of cancer. The company is focused on developing novel personalized cancer vaccines and inhibitors of myeloid-derived suppressor cells(MDSCs). The company's lead candidate is IFx-2.0 personalized cancer vaccine involves a simple injection into a patient’s tumor of a small amount of pDNA that encodes for an immunogenic bacterial protein which gets expressed on the surface of the patient’s tumor.
- Oct 2025Unattributed$1.5M
- Jun 2025Unattributed$2.2M
- Dec 2023Unattributed$1.7M
- Jul 2022Unattributed$9.1M
#2
Series A · Tampa, Florida · founded 2018$6Mraised▾
Betaliq is a developer of patented technology-based products for vision care. It has developed ophthalmic beta-blockers by using Novaliq’s patented EyeSol non-water formulation technology. The technology offers important advantages over traditional eye drops, including a drop size of approximately of the size of water-based drops, toxic preservatives, and others.
- May 2025Series A$416.3K
- Apr 2019Series A$6M
#3
Series A · Tampa, Florida · founded 2011$5.2Mraised▾
Developing innovative therapies targeting cancer and liver disease. This pharmaceutical company is dedicated to supplying new therapies for defeating deadly cancers and related diseases, improving the quality of life for patients with unmet needs. Founded as a spinoff, the company focuses on moving its pipeline of targeted radio-therapy, small molecule, and peptide-based drug compounds efficiently through the clinic to achieve rapid regulatory approval and patient access. Their research and development efforts are centered on novel therapies targeting aggressive cancers and liver disease. The company operates with a team of pharmaceutical scientists, discoverers, researchers, biologists, chemists, and business developers, emphasizing collaboration and innovation in drug discovery and development.
- Mar 2025Grant (prize money)$2.6M
- Feb 2025Grant (prize money)$2.6M
- Feb 2016Series A—
- Feb 2013Seed—
#4
Seed · Tampa, Florida · founded 2010 · 5 employees$2.7Mraised▾
VuEssence is developing diagnostic technology platforms for the treatment of stroke and neurological conditions. The company is developing diagnostic devices which use molecular analysis based on human genome and transcriptome data for the detection and management of stroke.
- Apr 2025Seed$47.5K
- Mar 2018Seed$1.5M
- May 2016Seed$1.2M
#5
Public · Tampa, Florida · founded 1996 · 5 employees$87.3Mraised▾
Developer of novel treatments for infectious diseases and oral mucositis as well as probiotics for oral health. Its lead drug AG013 is a live biotherapeutic candidate formulated as oral rinsing solution to deliver the therapeutic molecule Trefoil Factor 1 (TFF1) to the mucosal tissues in the oral cavity.
- Aug 2023Post IPO$850K
- Oct 2021Grant (prize money)$250K
- Aug 2021Grant (prize money)$256.7K
- Feb 2021Post IPO$22M
#6
Seed · Tampa, Florida · founded 2014 · 3 employees$750Kraised▾
Developing HLB-resistant citrus trees using CRISPR technology for Florida's citrus industry. This innovative company focuses on restoring the natural defenses of citrus trees against Huanglongbing (HLB), a devastating disease. Through precision breeding and collaboration with the University of Florida, they are creating new citrus varieties that exhibit reduced disease levels and vigorous growth. Their technology offers a breakthrough solution for citrus growers, aiming to revitalize the industry and mitigate the economic impact of HLB. This research and development company is committed to sustainable agriculture and offers a potential social impact by preserving a vital agricultural sector. They leverage gene editing to improve crop resilience and promote healthier citrus production.
- Mar 2025Grant (prize money)$650K
- Feb 2024Seed$500K
- Jun 2018Seed$250K
#7
Funding Raised · Tampa, Florida · founded 2013 · 22 employees$35Mraised▾
Innovative SI joint solutions for lasting pain relief and improved stability. They specialize in minimally invasive procedures for sacroiliac joint dysfunction, offering an alternative to traditional fusion surgery. Their flagship product, LINQ, is a single allograft implant designed to stabilize the SI joint and promote long-term fusion. They provide resources for patients and clinicians, including clinical evidence, educational materials, and support for reimbursement. They focus on improving patients' quality of life by addressing the root cause of SI joint pain, not just masking the symptoms. They offer a less invasive option with faster recovery times, helping patients regain joint stability and return to their daily activities.
- Jul 2023Conventional Debt$35M
#8
Series A · Tampa, Florida · founded 2018 · 20 employees$30Mraised▾
Developer of next-generation immunotherapy products. The lead product AlloStim is a bioengineered, non-genetically altered CD4+ Th1-like memory cell with anti-CD3/anti-CD28 coated microbead that has potent immunomodulatory properties and causes the down-regulation of checkpoint inhibitor molecules, such as PD-1/L1 and CTLA4. Chaperone Rich Cell Lysate are heat shock proteins purified from a lysed tumor or virally infected cells which preserve the chaperoned peptides that contain tumor neoantigens. The company also developed immunomodulatory vaccines that affect the immune system and provides immune counter-measures to prevent tumors and infected cells.
- Oct 2022Series A$20M
- Dec 2021Series A$10M
#9
Series E · Tampa, Florida · founded 1994 · 128 employees$116.1Mraised▾
Developer of therapeutics for infectious diseases The company has one commercialized product, Alinia (nitazoxanide), for diarrhea. The company's current pipeline includes one molecule NT-300 (nitazoxanide) for influenza and for RSV. Other compounds include RM-5061 (anti-infective) and RM-5038 and RM-5064 as broad-spectrum antiviral agents.
- Mar 2017Series E$13.8M
- Feb 2016Series D$10.7M
- Nov 2014Series D$10.8M
- Jun 2014Series D$15M
#10
Series C · Tampa, Florida · founded 2008$60Mraised▾
Developer of devices for treating cardint for people suffering from diabetes. It offers sirolimus-based drug delivery technologies which include Albuminus a polymer-based nano-carrier eluting stent for the treatment of coronary artery diseases, and MagicTouch a sirolimus coated balloon catheter for treating arterial venous fistula, coronary artery diseases, and peripheral arterial diseases, and diabetes.
- Aug 2018Series C$60M
- Aug 2018Conventional Debt—
- May 2017Seed$75K
- Aug 2011Seed$600K
#11
Acquired · Tampa, Florida · founded 2005$71.5Mraised▾
Sirion Therapeutics is a developer of ophthalmic products for eye care. It is a biopharmaceutical company that is engaged in the discovery, development, and commercialization of products for the protection and preservation of eyesight. It has developed Durezol, a topical steroid for postoperative inflammation and pain and uveitis ganciclovir, a topical antiviral for herpetic keratitis, cyclosporine, a topical immunomodulator for dry eye, fenretinide, an oral vitamin A binding protein antagonist for geographic atrophy associated with dry AMD.
- Aug 2009Series B$1.5M
- Apr 2007Series B$45M
- Jun 2006Series A$25M
- Seed—
#12
Series B · Tampa, Florida · founded 2005 · 2 employees$28.5Mraised▾
Developer of therapeutics for ophthalmic disorders. It offers Xiflam an orally administered NLRP3 inflammasome inhibitor to inhibit the pathological Cx43 hemichannel and modulate the activation of the inflammasome. It is focused on the ophthalmic indications of diabetic macular edema, age-related macular degeneration, and geographic atrophy.
- Jan 2021Series B$9.1M
- Jul 2012Series B$19.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.